마드리갈 파마슈티컬스, Inc.
US ˙ NasdaqGS ˙ US5588681057

SecurityMDGL / Madrigal Pharmaceuticals, Inc.
InstitutionRYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity
Latest Disclosed Ownership167 shares
Latest Disclosed Value $ 50,540
RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity reports 3.09% increase in ownership of MDGL / Madrigal Pharmaceuticals, Inc.

On August 27, 2025 - RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity filed a NPORT-P form disclosing ownership of 167 shares of Madrigal Pharmaceuticals, Inc. (US:MDGL) valued at $50,541 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 29, 2025 disclosing 162 shares of Madrigal Pharmaceuticals, Inc.. This represents a change in shares of 3.09% during the quarter. The current value of the position is $82,303 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-27 2025-06-30 NP Madrigal Pharmaceuticals EC US5588681057 167 5 3.09 51 -5.66 0.5617
2025-05-29 2025-03-31 NP Madrigal Pharmaceuticals EC US5588681057 162 -40 -19.80 54 -14.52 0.5700
2025-03-03 2024-12-31 NP Madrigal Pharmaceuticals EC US5588681057 202 -58 -22.31 62 12.73 0.6249
2024-11-29 2024-09-30 NP Madrigal Pharmaceuticals EC US5588681057 260 24 10.17 55 -16.67 0.4998
2024-08-29 2024-06-30 NP Madrigal Pharmaceuticals EC US5588681057 236 13 5.83 66 11.86 0.6028
2024-05-30 2024-03-31 NP Madrigal Pharmaceuticals EC US5588681057 223 -43 -16.17 60 -3.28 0.5050
2024-02-29 2023-12-31 NP Madrigal Pharmaceuticals EC US5588681057 266 21 8.57 62 74.29 0.5044
2023-11-29 2023-09-30 NP Madrigal Pharmaceuticals EC US5588681057 245 37 17.79 36 -27.08 0.3098
2023-08-28 2023-06-30 NP Madrigal Pharmaceuticals EC US5588681057 208 -90 -30.20 48 -33.33 0.3792
2023-05-30 2023-03-31 NP Madrigal Pharmaceuticals EC US5588681057 298 -1,316 -81.54 72 -48.20 0.5468
2019-11-27 2019-09-30 NP Madrigal Pharmaceuticals EC US5588681057 1,614 1,614 139 0.7383
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.